Form 8-K - Current report:
SEC Accession No. 0000950170-23-027939
Filing Date
2023-06-14
Accepted
2023-06-14 16:03:48
Documents
14
Period of Report
2023-06-14
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K glue-20230614.htm   iXBRL 8-K 103579
2 EX-3.1 glue-ex3_1.htm EX-3.1 23161
  Complete submission text file 0000950170-23-027939.txt   293121

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT glue-20230614_def.xml EX-101.DEF 14120
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT glue-20230614.xsd EX-101.SCH 2906
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT glue-20230614_pre.xml EX-101.PRE 14180
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT glue-20230614_lab.xml EX-101.LAB 20554
8 EXTRACTED XBRL INSTANCE DOCUMENT glue-20230614_htm.xml XML 6531
Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40522 | Film No.: 231014097
SIC: 2836 Biological Products, (No Diagnostic Substances)